Dyslipidaemias

Current Care Summary
Working group set up by the Finnish Medical Society Duodecim and Finnish Society of Internal Medicine
27.10.2020

Current Care Guideline «Dyslipidemiat»1 and Summary «Dyslipidemiat»2 in Finnish

The updated guideline on dyslipidaemia is in concordance with European guidelines (2019). Management of dyslipidaemias aims to reduce the risk of atherosclerotic diseases, determined by cardiovascular risk assessment. Therapeutic targets for plasma LDL cholesterol range from concentrations < 1.4 to < 1.8 mmol/l (persons at very high or high risk), and from < 2.6 mmol/l to < 3.0 mmol/l (moderate or low risk). Changes in lifestyle (diet, physical activity and nonsmoking) are the cornerstones. Drugs, mainly statins, ezetimibe, PCSK9 inhibitors, and in some cases fibrates or resins are initiated as appropriate to reach the targets.

Timo Strandberg (Chair)

Mikko Syvänne

Juhani Kahri

Katriina Kukkonen-Harjula

Tiina Laatikainen

Niina Matikainen

Harri Niinikoski

Ursula Schwab

Hannu Vanhanen

Alpo Vuorio